Skip to main content
Fig. 3 | Journal of Pharmaceutical Policy and Practice

Fig. 3

From: mRNA vaccine development during the COVID-19 pandemic: a retrospective review from the perspective of the Swiss affiliate of a global biopharmaceutical company

Fig. 3

Source: Federal Office of Public Health https://www.covid19.admin.ch/api/data/20220705-0r3tf4ch/sources/COVID19VaccSymptoms.csv. Accessed 15 Nov 2023

Vaccine administration and adverse vaccination reaction reporting in Switzerland and Liechtenstein. Left: cumulative total administered doses of mRNA vaccines from the start of the Swiss vaccination program to the end of 2021 (mRNA-1273 and BNT162b2 were the only conditionally approved mRNA COVID-19 vaccines during this perioxd). Federal Office of Public Health, www.covid19.admin.ch. Right: cumulative totals of adverse vaccination reactions (blue; non-serious, green; serious) following mRNA vaccine administration reported to Swissmedic during the same period. Data on adverse vaccination reactions were generally released weekly during this period.

Back to article page